false
0001812173
0001812173
2025-06-27
2025-06-27
0001812173
RBOT:ClassCommonStockParValue0.0001PerShareMember
2025-06-27
2025-06-27
0001812173
RBOT:WarrantsToPurchaseOneShareOfClassCommonStockEachAtExercisePriceOf11.50PerShareMember
2025-06-27
2025-06-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June
27, 2025
VICARIOUS SURGICAL INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-39384 |
|
87-2678169 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
| 78 Fourth Avenue |
|
|
| Waltham, Massachusetts |
|
02451 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (617) 868-1700
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange
on which registered |
| Class A common stock, par value $0.0001 per share |
|
RBOT |
|
The New York Stock Exchange |
| Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share |
|
RBOT WS |
|
The New York Stock Exchange |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Equity Plan Amendment
On June 27, 2025, Vicarious
Surgical Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual
Meeting, the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2021 Equity
Incentive Plan (the “2021 Plan”) that includes the following material changes:
| ● | The aggregate number of shares
of the Company’s common stock that may be issued under the 2021 Plan was increased by 311,046 shares, subject to adjustment for
certain changes in the Company’s capitalization. |
| ● | The aggregate maximum number
of shares of the Company’s common stock that may be issued pursuant to the exercise of incentive stock options under the 2021 Plan
was increased by 311,046 shares, subject to adjustment for certain changes in the Company’s capitalization. |
A detailed summary of
the material features of the 2021 Plan, as amended by the Plan Amendment, is set forth in the Company’s definitive proxy statement
for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2025 (the “Proxy Statement”). That summary
and the foregoing description of the Plan Amendment are qualified in their entirety by reference to the full text of the 2021 Plan, as
amended by the Plan Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Non-Employee Director
Compensation Policy
On April 21, 2025, the
Company’s Board of Directors (the “Board”) formed a Technology and Product Committee (the “Product Committee”)
and appointed Dr. Victoria Carr-Brendel, Beverly Huss and Randy Clark as members, with Dr. Carr-Brendel serving as chairperson. Effective
June 27, 2025, the Board approved an amendment and restatement of the Company’s non-employee director compensation policy (as amended
and restated, the “Policy”) to (i) provide for annual cash retainers payable to members of and the chairperson of the Product
Committee and (ii) provide that the Compensation Committee may, in its discretion, grant initial and subsequent annual equity awards to
members of the Board with values less than the amounts specifically set forth in the Policy. Pursuant to the Policy, as amended and restated,
non-employee directors receive annual retainers as follows:
| Position | |
Retainer | |
| Chairperson of the Board (Additional Retainer) | |
$ | 35,000 | |
| Member of the Board | |
$ | 40,000 | |
| Chairperson of the Audit Committee | |
$ | 18,000 | |
| Member of the Audit Committee | |
$ | 6,300 | |
| Chairperson of the Compensation Committee | |
$ | 14,250 | |
| Member of the Compensation Committee | |
$ | 5,500 | |
| Chairperson of the Nominating and Corporate Governance Committee | |
$ | 10,000 | |
| Member of the Nominating and Corporate Governance Committee | |
$ | 4,650 | |
| Chairperson of the Product and Technology Committee | |
$ | 14,250 | |
| Member of the Product and Technology Committee | |
$ | 5,500 | |
These fees are payable
in arrears in quarterly installments no later than the fifteenth day following the end of each calendar quarter, provided that the amount
of such payment will be prorated for any portion of such quarter that a director is not serving on the Board, on such committee or in
such position. Non-employee directors may elect to receive an equity award with a grant date fair value of the retainer amounts in lieu
of receiving cash in such amounts. Non-employee directors are also reimbursed for reasonable out-of-pocket business expenses incurred
in connection with attending meetings of the Board and any committee of the Board on which they serve and in connection with other business
related to the Board. Directors may also be reimbursed for reasonable out-of-pocket business expenses in accordance with the Company’s
travel and other expense policies, as may be in effect from time to time.
In addition, the Company
will grant to new non-employee directors upon their initial election to the Board, on the date that the non-employee director is first
appointed or elected to the Board, either:
| |
● |
A number of restricted stock units having an aggregate value equal to $301,800 or such lesser amount as determined by the Compensation Committee, determined by dividing (A) $301,800 or such lesser amount by (B) the closing price of the Class A common stock on the NYSE on the date of the grant; or |
| |
|
|
| |
● |
If specified by the Compensation Committee, a number of stock options to purchase Class A common stock having an aggregate grant date fair value equal to $301,800 or such lesser amount as determined by the Compensation Committee, based on the Black Scholes value of such options on the date of the grant. |
Unless otherwise specified
by the Board or the Compensation Committee at the time of grant, each of the initial grants will vest in equal monthly installments over
36 months from the date of the grant, subject to the non-employee director’s continued service as a director through each applicable
vesting date.
Furthermore, each non-employee
director who has been serving on the Board for at least six months as of the date of any annual meeting of stockholders will receive,
on the date of such annual meeting, either:
| |
● |
A number of restricted stock units having an aggregate value equal to $145,000 or such lesser amount as determined by the Compensation Committee, determined by dividing (A) $145,000 or such lesser amount by (B) the average price of the Class A common stock on the NYSE for the 60 days prior to the applicable grant date; or |
| |
|
|
| |
● |
If specified by the Compensation Committee, a number of stock options to purchase Class A common stock having an aggregate grant date fair value equal to $145,000 or such lesser amount as determined by the Compensation Committee, based on the Black Scholes value of such options on the date of the grant. |
Each non-employee director
who has been serving on the Board for less than six months as of the date of any annual meetings of stockholders, will, unless otherwise
specified by the Board or the Compensation Committee at the time of grant, receive a restricted stock unit award prorated for the portion
of the year served on the Board. Unless otherwise specified by the Board or the Compensation Committee at the time of grant, each of these
subsequent grants will vest on the earlier to occur of (i) one day prior to the next annual meeting of stockholders held after the date
of grant, or (ii) the one year anniversary of the date of grant, subject to the non-employee director’s continued service as a director
through the applicable vesting date.
The foregoing description
of the Policy does not purport to be complete and is qualified in its entirety by reference to the full text of the Policy, as amended
and restated, a copy of which is filed as Exhibit 10.2 hereto and incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote
of Security Holders.
On June 27, 2025, the
Company held the Annual Meeting. At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described
in more detail in the Proxy Statement. At the Annual Meeting, there were an aggregate of 4,095,496 shares of Class A common stock and
Class B common stock present or represented by proxy, which represented approximately 90.0% of the outstanding total voting power of the
shares of Class A common stock and Class B common stock entitled to vote at the Annual Meeting (voting together as a single class), which
constituted a quorum for the transaction of business. Holders of the Company’s Class A common stock were entitled to one vote for
each share held as of close of business on April 28, 2025 (the “Record Date”), and holders of the Company’s Class B
common stock were entitled to 20 votes for each share held as of the Record Date.
The following actions were taken at the Annual
Meeting:
1. The following nominees were elected to
serve on the Board until the Company’s 2026 annual meeting of stockholders, based on the following votes:
| Nominee | |
Votes
For | | |
Votes
Withheld | | |
Broker
Non-Votes | |
| Adam Sachs | |
| 14,725,845 | | |
| 7,119 | | |
| 1,788,342 | |
| Sammy Khalifa | |
| 14,718,479 | | |
| 14,485 | | |
| 1,788,342 | |
| Victoria Carr-Brendel, Ph.D. | |
| 14,301,946 | | |
| 431,018 | | |
| 1,788,342 | |
| Randy Clark | |
| 14,719,241 | | |
| 13,723 | | |
| 1,788,342 | |
| David Ho, M.D. | |
| 14,441,722 | | |
| 291,242 | | |
| 1,788,342 | |
| Beverly Huss | |
| 14,302,055 | | |
| 430,909 | | |
| 1,788,342 | |
| Donald Tang | |
| 14,726,431 | | |
| 6,533 | | |
| 1,788,342 | |
| Fuad Ahmad | |
| 14,726,300 | | |
| 6,664 | | |
| 1,788,342 | |
| Joseph Doherty | |
| 14,726,764 | | |
| 6,200 | | |
| 1,788,342 | |
2. The amendment to the
2021 Plan pursuant to the Plan Amendment was approved, based on the following results:
| Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| | 14,678,240 | | |
| 50,817 | | |
| 3,907 | | |
| 1,788,342 | |
3. The appointment of
Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31,
2025 was ratified, based on the following results:
| Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| | 16,492,037 | | |
| 18,687 | | |
| 10,582 | | |
| 1,788,342 | |
Item 7.01. Regulation FD Disclosure.
On June 30, 2025, the
Company issued a press release announcing the election of Fuad Ahmad and Joseph Doherty to the Board. A copy of the press release is furnished
as Exhibit 99.1 hereto.
The information in this
Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit No. |
|
Description |
| 10.1 |
|
Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended, and forms of agreement thereunder |
| 10.2 |
|
Amended and Restated Non-Employee Director Compensation Policy |
| 99.1 |
|
Press Release dated June 30, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
VICARIOUS SURGICAL INC. |
| |
|
|
| |
By: |
/s/ Adam Sachs |
| |
Name: |
Adam Sachs |
| |
Title: |
Chief Executive Officer |
Date: June 30, 2025
4
